Bio-Rad Third-Quarter 2026 Earnings Results Conference Call and Webcast - BIO-RAD LABORATORIES INC

Financial Performance:

• Total Q3 2026 revenue was $656 million, a 0.5% increase reported and 0.7% currency-neutral year-over-year (YoY), marking the first currency-neutral growth quarter of 2026.
• Life Science sales were $255 million (down 2.8% reported, 2.4% currency-neutral), driven by lower process chromatography but offset by DDPCR growth; excluding process chromatography, revenue grew 2.5%.
• Clinical Diagnostics sales reached $402 million (up 2.7% reported, 2.8% currency-neutral), fueled by timing of orders and strength in Quality Systems and diabetes products.
• Consolidated GAAP gross margin was 50.1% (vs. 52.6% prior year), primarily due to restructuring charges; Non-GAAP gross margin expanded to 54.5% (vs. 53.5% prior year).
• Non-GAAP operating margin improved to 12.8% (vs. 11.8% prior year), with GAAP operating loss of $15 million (vs. $65 million income prior year) due to a $50 million non-cash impairment of intangible assets.
• Non-GAAP net income was $72 million ($2.65 diluted EPS) compared to $61 million ($2.26 EPS) in Q3 2025.
• SG&A was $257 million (39.2% of sales); Non-GAAP SG&A was $214 million (32.6% of sales). R&D was $71 million (10.9% of sales); Non-GAAP R&D was $60 million.
• Free cash flow guidance for full-year 2026 remains $290–$340 million, with $210 million generated in the first nine months.

Guidance and Future Outlook:

• Full-year 2026 currency-neutral revenue growth is reaffirmed between -3% and +0.5%, expected near the midpoint.
• Life Science currency-neutral growth guided for -3% to -1%; Clinical Diagnostics guided for -3% to +1%.
• Q4 2026 revenue is expected to sequentially increase 5–6% on a reported basis.
• Full-year 2026 Non-GAAP gross margin guided for the upper half of 53–54%; Q4 margin expected to decline sequentially due to product mix shift toward instruments, process chromatography headwinds, and fuel costs.
• Full-year 2026 Non-GAAP operating margin guided for the upper half of 10–12%.
• Management anticipates 2027 will be focused on returning to positive growth and margin expansion, though specific 2027 revenue guidance will be provided at year-end.
• Acquisitions: Open to $100–$500 million revenue deals that offer differentiation and margin improvement; no transformative deals sought.
• Capital Allocation: Opportunistic share repurchases (not systematic); continued investment in CapEx/innovation; potential monetization of Sartorius stake remains an option.

Business Segments and Product Lines:

• DDPCR (Droplet Digital PCR): Instrument revenue grew >20% for the third consecutive quarter, driven by conversions from qPCR and competitive wins; considered a durable long-term growth driver.
• Chromatography: Process chromatography revenue improved sequentially throughout 2026 but is expected to decline in Q4; Q2 2026 full-year revenue expected to be up YoY.
• Innovation: Launched ChemiDot Pro imaging system (Western blot) with AI-enhanced analytical algorithms; expanded Foresight Pro chromatography portfolio with Renuvia resins.
• Portfolio Discipline: Recorded $50 million non-cash impairment on intangible assets to prioritize high-return R&D programs and accelerate product cadence.
• Supply Chain: Advancing operational efficiency, inventory optimization, and manufacturing footprint optimization to support margin expansion.

Market and Competitive Landscape:

• Biopharma: Seeing gradual recovery in customer activity, shifting from large pharma later-stage to discovery roles; viewed as constructive for future demand.
• Academic/Government (US): Challenging environment with NIH outlays down ~15%; Q4 outlook assumes no recovery in these markets.
• China (APAC): Returned to growth in Q3 driven by order timing and favorable comparisons; faces pricing pressure from domestic suppliers and NHSA guidelines, estimated to impact 2027 revenue by middle single-digit millions.
• EMEA/Middle East: Logistics costs elevated with supply chain disruptions expected to continue into 2027.
• Regulatory: Monitoring PAMA (Medicare reimbursement rates); current data shows no meaningful change in customer purchasing behavior, with limited indirect impact expected in 2027.

Risks and Challenges:

• Pricing Pressure: Ongoing pricing pressure in China's IVD market due to National Healthcare Security Administration guidelines.
• Funding Constraints: Continued softness in US academic and government funding affecting Life Science demand.
• Supply Chain: Elevated logistics costs and potential disruptions in the Middle East extending into 2027.
• Market Volatility: Mixed end-market conditions with uneven recovery speeds across segments and geographies.
• Restructuring: Ongoing execution of a program intended to deliver $30–$35 million in net savings by 2028.

Management Commentary and Tone:

• Tone: Cautiously optimistic; management expressed encouragement over progress in currency-neutral growth, DDPCR performance, and margin expansion, despite "mixed" market conditions.
• Strategic Focus: Emphasized three priorities: strengthening execution, improving cost structure, and increasing enterprise productivity.
• AI Strategy: Highlighting dual use of AI for internal operational efficiency and enhancing product capabilities (e.g., ChemiDot Pro).
• Board Governance: Actively evaluating board composition expansion to bring in broader operational experience; updates expected soon.
• Shareholder Relations: Dialogue with Elliott Management described as "active and productive" with broad alignment on objectives.

Analyst Questions and Answers:

• 2027 Outlook: Management confirmed a goal of returning to positive growth in 2027 but noted lingering headwinds; specific revenue guidance to be provided at year-end.
• DDPCR Sustainability: Confidence remains high in DDPCR instrument growth despite challenging comparisons, citing new customer acquisition and platform utilization ramp-up.
• China & PAMA Impact: China's NHSA guidelines projected to impact 2027 revenue by middle single-digit millions; PAMA not expected to materially impact purchasing behavior in the near term.
• Academic vs. Biopharma: Academic spending remains subdued pending midterm election results; Biopharma demand is improving and expanding into discovery.
• Capital Deployment: Share repurchases are opportunistic; Sartorius stake remains a potential monetizable asset. M&A focus remains on $100–$500M revenue deals for differentiation.
• Restructuring Progress: The $30–$35 million savings target remains on track, with full realization expected in 2028.

Other Key Points:

• Tariffs: Company absorbs tariff surcharges in cost of goods sold; any future tariff refunds will be recognized on a GAAP basis only and excluded from Non-GAAP results.
• Sartorius Stake: No change in the stance that the equity stake in Sartorius AG is a monetizable asset, to be acted upon if a value-creating scenario arises.
• Q4 Seasonality: Q4 is historically the strongest quarter for revenue.
• Event: Management will attend the UBS Global Healthcare Conference the following week.